Suministro de prótesis mamarias y expansores para el Hospital Transversal del Consorci Sanitari Integral
TED · 305155-2026Award notice · modificationawardedNo deadline given
Value
Estimated—
Awarded€226,050 · 226,050 EUR
WinnerBIOCLAN, S.L. | MOTIVA IMPLANTS SPAIN
Who already wins at this buyer
Firms with recorded awards from Consorci Sanitari Integral in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| Laboratorios LEO Pharma, S.A. | 2 | €787,247 | 2026-05-07 |
| ROCHE DIAGNOSTICS, S.L.U. | 1 | €2,082,222 | 2026-07-21 |
| UCB PHARMA, S.A. | 1 | €1,887,515 | 2026-06-05 |
| BIOCON BIOLOGICS SPAIN | 1 | €528,490 | 2026-07-10 |
| Abast Medica S.L. | 1 | €409,179 | 2026-06-30 |
Full buyer profile: what Consorci Sanitari Integral buys and who wins it →
CPV codes
33184400 Medical equipment & pharmaceuticalsDescription
Suministro de prótesis mamarias y expansores para el Hospital Transversal del Consorci Sanitari Integral
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-05-27 | Suministro de infusores elastoméricos para el Consorci Sanitari Integral | Consorci Sanitari Integral ES | 94% |
| 2026-06-26 | Suministro e instalación de lámparas quirúrgicas para el Consorcio Sanitario Integral | Consorci Sanitari Integral ES | 93% |
| 2026-06-30 | Suministro y mantenimiento de monitores multiparamétricos por el área quirúrgica del Consorci Sanitari Integral | Consorci Sanitari Integral ES | 93% |
| 2026-06-30 | Suministro de Expansores y Prótesis Mamarias para el Servicio de Cirugía Plástica de la Organización Sanitaria Integrada Ezkerraldea Enkarterri Cruces | OSAKIDETZA - Servicio Vasco de Salud - Hospital Universitario Cruces (Impulsora) ES | 93% |
| 2026-05-04 | Servicio de seguridad y vigilancia en los centros del Consorci Sanitari Integral | Consorci Sanitari Integral ES | 93% |
| 2026-05-19 | CONTR/2026/000000074 | Institut d'Assistència Sanitària (IAS) ES | 92% |